anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a composition having a synergistic health function by paying attention to the cell activating action, flood purifying action, blood flow ameliorating action, antiulcer action, and active oxygen-elimination action of an extract of bamboo grass and using an extract of Euphausia and/or an extract of Juncus in combination, and a cosmetic and a food and drink containing the same.  <P>SOLUTION: The composition comprises an extract of bamboo grass, an extract of Euphusia and/or an extract of Juncus. The cosmetic for preventing rough dry skin comprises this composition. The health food and drink comprises this composition. The composition, cosmetic and food and drink use Sasa senanensis or Sasa veitchii as the bamboo grass.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Participants will take a placebo capsule daily for 3 months. Placebo will be methylcellulose encapsulated into an opaque closed gelatin capsule for blinding. Capsules will be placed in a labeled bottle, with the contents only identifiable by a code on the package label and only the compounding pharmacy and the unblinded pharmacist at Houston Methodist Investigational Drug Service will know the code definition.
FIELD: medicine, immunology, pharmacy. SUBSTANCE: invention proposes the use of β-heptyl- -glycoside-N-acetylmuramyl-L-alanyl-D-isoglutamine (C 7 H 15МПД ) as an immunomodulating agent and a pharmaceutical composition exhibiting antitumor activity. Composition has an effective amount of β-heptylglycoside MPD and physiologically acceptable filling agents. Preparation promotes an activation of the main links of immunity and can be used for immunity correction in the cases of severe immunodeficiencies. EFFECT: enhanced effectiveness of an immunomodulating activity of an agent. 5 cl, 7 tbl
This review focuses on the initial imaging in the reproductive age adult population with acute pelvic pain, including patients with positive and negative beta-human chorionic gonadotropin (β-hCG) levels with suspected gynecological and nongynecological etiology. For all patients, a combination of transabdominal and transvaginal pelvic ultrasound with Doppler is usually appropriate as an initial imaging study. If nongynecological etiology in patients with negative β-hCG is suspected, then CT of the abdomen and pelvis with or without contrast is also usually appropriate. In patients with positive β-hCG and suspected nongynecological etiology, CT of the abdomen and pelvis with contrast and MRI of the abdomen and pelvis without contrast may be appropriate. In patients with negative β-hCG and suspected gynecological etiology, CT of the abdomen and pelvis with contrast, MRI of pelvis without contrast, or MRI of pelvis with and without contrast may be appropriate. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation.
Urinary omics has become a powerful tool for elucidating pathophysiology of glomerular diseases. However, no urinary omics analysis has been performed yet on renal AA amyloidosis. Here, we performed a comparative urine proteomic and metabolomic analysis between recently diagnosed renal AA amyloidosis (AA) and membranous nephropathy (MN) patients. Urine samples of 22 (8 AA, 8 MN and 6 healthy control) patients were analyzed with nLC-MS/MS and GC/MS for proteomic and metabolomic studies, respectively. Pathological specimens were scored for glomerulosclerosis and tubulointerstitial fibrosis grades. Functional enrichment analysis between AA and control groups showed enrichment in cell adhesion related sub-domains. Uromodulin (UMOD) was lower, whereas ribonuclease 1 (RNase1) and α-1-microglobulin/bikunin precursor (AMBP) were higher in AA compared to MN group. Correlations were demonstrated between UMOD-proteinuria (r = -0.48, p = 0.03) and AMBP-eGFR (r = -0.69, p = 0.003) variables. Metabolomic analysis showed myo-inositol and urate were higher in AA compared to MN group. A positive correlation was detected between RNase1 and urate independent of eGFR values (r = 0.63, p = 0.01). Enrichment in cell adhesion related domains suggested a possible increased urinary shear stress due to amyloid fibrils. UMOD, AMBP and myo-inositol were related with tubulointerstitial damage, whereas RNase1 and urate were believed to be related with systemic inflammation in AA amyloidosis. SIGNIFICANCE: Urinary omics studies have become a standard tool for biomarker studies. However, no urinary omics analysis has been performed yet on renal AA amyloidosis. Here, we performed a comparative urinary omics analysis between recently diagnosed renal AA amyloidosis (AA), membranous nephropathy (MN) patients and healthy controls. Pathological specimens were scored with glomerulosclerosis (G) and tubulointerstitial fibrosis (IF) grades to consolidate the results of the omics studies and correlation analyzes. Functional enrichment analysis showed enrichment in cell adhesion related sub-domains due to downregulation of cadherins; which could be related with increased urinary shear stress due to amyloid deposition and disruption of tissue micro-architecture. In comparative proteomic analyzes UMOD was lower, whereas RNase1 and AMBP were higher in AA compared to MN group. Whereas in metabolomic analyzes; myo-inositol, urate and maltose were higher in AA compared to MN group. Correlations were demonstrated between UMOD-proteinuria (r = -0.48, p = 0.03), AMBP-eGFR (r = -0.69, p = 0.003) and between RNase1-Urate independent of eGFR values (r = 0.63, p = 0.01). This study is the first comprehensive urinary omics analysis focusing on renal AA Amyloidosis to the best of our knowledge. Based on physiologic roles and clinicopathologic correlations of the molecules; UMOD, AMBP and myo-inositol were related with tubulointerstitial damage, whereas RNase1 and urate were believed to be increased with systemic inflammation and endothelial damage in AA amyloidosis.
Participants will receive 1 cycle of neoadjuvant Nivolumab or Nivolumab + Azacitidine, followed by surgery to render them in surgical remission. Subsequently they will continue to receive Nivolumab or Nivolumab + Azacitidine for 12 additional cycles or until recurrence, whichever occurs first. Once the recommended Phase II dose (RP2D) is identified during Phase I, the Dose Expansion Phase II will be opened at this dose level. The Phase II portion of the study will consist of a maximum 33 evaluable patients (27-30 in addition to the 3-6 enrolled at RP2D on the Phase I portion).
The invention discloses a pulse data classification method and device based on semi-supervised discrimination projection. The specific classification method comprises the following steps: 1. pressure pulse data is collected. 2. And (3) preprocessing and feature extraction are carried out on the data collected in the step (1). 3. And establishing a semi-supervised discrimination projection model, searching an optimal subspace by using a projection matrix, clustering in the space, labeling a label-free sample, and adding the next round of training to realize semi-supervised learning of pulse data. 4. And analyzing the projection matrix, and acquiring the contribution degree of each characteristic to the current task by solving the 'row normalization two-norm' of the projection matrix. The pulse data classification device is used for realizing the classification steps. The invention provides a high-precision pulse data classification task tool through a judgment projection method, so that the feature importance is quantized, and a good experimental effect is obtained.
Sustainable diets are gaining interest as a possible approach to tackle climate change and the global extent of obesity. Yet, the association between sustainable diets and adiposity remains unclear. We performed a systematic review and meta-analysis, calculating summary relative risks and 95% confidence intervals (CI). We pooled maximally adjusted risk estimates, assessed heterogeneity and publication bias, calculated the E-value, and evaluated the risk of bias across the included studies. A total of eight studies were eligible for analysis. Comparing the highest versus the lowest levels of adherence to sustainable diets, the pooled effect estimate was 0.69 (95% CI = 0.62-0.76) for overweight and 0.61 (95% CI = 0.47-0.78) for obesity. These results suggest that sustainable diets may decrease the risk of overweight/obesity and therefore could serve as enablers for improving both public and planetary health. An agreed-upon clear definition of sustainable diets would enhance the comparability of future studies in this area.
A gene encoding a protein regulating aureobasidin sensitivity obtained from a mold belonging to the genus  Aspergillus  or its functional derivative. A cloning method with the use of at least a part of the same as a probe. The antisense DNA or RNA of this gene. Processes for producing a recombinant plasmid, a transformant, a protein, etc. of the above-mentioned gene. A nucleic acid probe hybridizable with the above-mentioned gene and a method for detecting the gene with the use of the same. Useful in the diagnosis and treatment of diseases such as mycosis.
FIELD: veterinary microbiology, biotechnology. SUBSTANCE: method of vaccine preparing against STREPTOCOCCUS in nutria. The strain Str. zooepidemicus is grown on meat-peptone broth with 1% glucose solution at 37-38 C for 18-24 h. To this time bacterial mass concentration must be 4 x 10m.k./1 ml, not less. Prepared cultural medium is subjected for freezing-thawing, liquid fractions were separated, inactivated with 0.3-0.4% formalin solution. After inactivation sterile adjuvant, 3% aluminium hydroxide solution, is added to bacterial mass. Prepared vaccine provides formation stable prolonged immunity. Epizootic effectiveness of vaccine is 98.4% of all vaccinated animals. EFFECT: enhanced effectiveness of vaccine.
This is a stratified cluster non-inferiority randomized controlled trial with randomization of participating clusters into a 'telemedicine' or 'group care' arm. Sites will be stratified into 'high volume' (\>500 deliveries/year) and 'low volume' (\<500 deliveries per year). Randomization will be within each strata. Patients attending sites randomized to telemedicine will be recruited by research staff.
Serum Electrolytes: Hyperkalemia, (see PRECAUTIONS); hyponatremia, (see PRECAUTIONS: Drug Interactions; With diuretics).

BUN/Serum Creatinine: Elevations, usually transient and minor, of BUN or serum creatinine have been observed. In placebo-controlled clinical trials, there were no significant differences in the number of patients experiencing increases in serum creatinine (outside the normal range or 1.33 times the pre-treatment value) between the fosinopril and placebo treatment groups. Rapid reduction of longstanding or markedly elevated blood pressure by any antihypertensive therapy can result in decrease in the glomerular filtration rate and, in turn, lead to increases in BUN or serum creatinine. (See PRECAUTIONS: General.)

Hematology: In controlled trials, a mean hemoglobin decrease of 0.1 g/dL was observed in fosinopril treated patients. In individual patients decreases in hemoglobin or hematocrit were usually transient, small, and not associated with symptoms. No patient was discontinued from therapy due to the development of anemia. Other: Neutropenia (see WARNINGS), leukopenia and eosinophilia.

Liver Function Tests: Elevations of transaminases, LDH, alkaline phosphatase and serum bilirubin have been reported. Fosinopril therapy was discontinued because of serum transaminase elevations in 0.7% of patients. In the majority of cases, the abnormalities were either present at baseline or were associated with other etiologic factors. In those cases which were possibly related to fosinopril therapy, the elevations were generally mild and transient and resolved after discontinuation of therapy.
The hypoxic microenvironment, characterized by significantly reduced oxygen levels within tissues, has emerged as a critical factor in the pathogenesis and progression of various autoimmune diseases (AIDs). Central to this process is the hypoxia-inducible factor-1 (HIF-1), which orchestrates a wide array of cellular responses under low oxygen conditions. This review delves into the multifaceted roles of the hypoxic microenvironment in modulating immune cell function, particularly highlighting its impact on immune activation, metabolic reprogramming, and angiogenesis. Specific focus is given to the mechanisms by which hypoxia contributes to the development and exacerbation of diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), and dermatomyositis (DM). In these conditions, the hypoxic microenvironment not only disrupts immune tolerance but also enhances inflammatory responses and promotes tissue damage. The review also discusses emerging therapeutic strategies aimed at targeting the hypoxic pathways, including the application of HIF-1α inhibitors, mTOR inhibitors, and other modulators of the hypoxic response. By providing a comprehensive overview of the interplay between hypoxia and immune dysfunction in AIDs, this review offers new perspectives on the underlying mechanisms of these diseases and highlights potential avenues for therapeutic intervention.
There is a long debate whether monopoloar or blunt dissection should be adopted in TEP to minimise the chance of seroma formation. This study aims at study the effect on seroma formation (and pre-peritoneal drain output) by 2 techniques in randomised controlled trial.

all male and female patients presented with first occurrence, unilateral inguinal hernia anticipated for laparoscopic TEP are included into study after informed consent. Patients are randomized into "diathermy-preferred" (DP) group and "blunt dissection-preferred" (BDP) group just before commence of operation after general anaethesia. Surgeons are instructed to use monopolar energy as main dissection method for whole operation if possible (DP), where as blunt dissection is the preferred choice in BDP group but it is allowed to use monopolar energy if needed. Total energy time is measured by a specially designed device attaching to the monopolar pedals as accurate as to millisecond (ms). Pre-peritoneal drains are inserted for drainage and removed 23 hours after operation. Energy time, drainage output, ultrasonic seroma sizes at day 1, day 6, 1 month post-operations, recurrence are compared between 2 groups.
TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 7. TAR-200 releases gemcitabine gradually during the 7 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 28, which is the day of the TURBT.
Isocitrate dehydrogenases (IDH) are enzymes that catalyze oxidative decarboxylation of isocitrate into alpha-ketoglutarate (α-KG). IDH1 and IDH2 mutations in AML give the enzymes neomorphic enzymatic activity to transform α-KG to D-2HG, an oncometabolite which acts as a competitive inhibitor of dioxygenases, and causes dysregulation of TET2 and histone demethylases, consequently leading to epigenetic reprogramming of a cell, blocking differentiation and contributing to a transformed phenotype, and leukemogenesis. Investigators plan to recruit 300 adult AML patients (newly diagnosed or relapsed). 10mL of peripheral blood or marrow blood will be obtained from routine practice blood/marrow sampling specimens (no extra venipuncture or bone marrow aspiration would be required) and sent for routine tests such as cytogenetics, immunophenotyping, and gene mutation analyses. IDH1 R132, IDH2 R140, and IDH2 R172 mutations will be screened by PCR followed by Sanger sequencing, as previously described.

Investigators will first assess the incidence of IDH1 and IDH2 mutations in adult AML patients, and then explore their associations with the patients' clinical course, cytogenetic, and molecular characteristics as well as with treatment response and outcome. Investigators also seek to delineate the similarities and distinctions among IDH mutation variants at IDH1-R132, IDH2-R140 and IDH2-R172, both clinically and molecularly (including cytogenetics, immunophenotyping, mutation co-occurrence patterns).
<P>PROBLEM TO BE SOLVED: To provide a new whitening agent that inhibits the expression of a c-kit gene and is expected to have a better effect.  <P>SOLUTION: Any plant of Curcuma zedoaria Roscoe, Terminalia chebula Retz, Sparganium simplex Hudson and Hydrangea macrophilla var. thunbergii or Hydrangea macrophylia (Thnb.) Ser. Subsp. Serrata (Thunmb.) Makino, Hydrangea Sering var. thunbergill Sugimoto, or an extract thereof is used as a c-kit gene expression inhibitor. Because these plants and extracts thereof suppress expression of the c-kit present at the surface of cells such as a melanocyte, a mast cell and a digestive tract stroma oncocyte and prevent stimulation related to an SCF, they are expected to show whitening effect by suppressing melanogenesis, to show antiallergic function by suppressing multiplication and differentiation from the mast cell or to suppress a digestive tract stroma tumor.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The invention discloses a cat interferon omega, a preparation method thereof and application thereof in antivirus. The amino acid sequence of the cat interferon omega is shown in SEQ ID NO. 2. Preferably, the nucleotide sequence for coding the feline interferon omega is shown in SEQ ID NO. 1. In addition, the invention also discloses a method for preparing the feline interferon omega and application of the feline interferon omega in preparing antiviral drugs. The invention adopts a method of virus stimulation (feline enterocoronavirus) and interferon inducer stimulation (poly I: C) to stimulate pet cats so as to induce the expression of feline interferon genes. Then, a cat interferon omega gene is obtained through PCR amplification, and cell tests show that the cat interferon omega obtained by the invention has obvious antiviral activity and is superior to the existing known cat interferon. The invention lays a foundation for further research and development and application of the cat interferon product.
A prospective, parallel, single-blind clinical study using stratified randomization of the effectiveness, tolerability and safety of the drug Povidone-iodine produced by BelAseptika JSC, in adult patients with purulent-inflammatory processes of the skin and soft tissues due to chronic venous insufficiency\", phase I-II of the wound process . All patients will receive systemic traditional therapy for the underlying and concomitant diseases.
Epidural spinal cord stimulation (SCS) is indicated for the treatment of intractable pain and is widely used in clinical practice. In previous basic research, the therapeutic effects of SCS have been demonstrated for epileptic seizure. However, the mechanism has not yet been elucidated. In this study, we investigated the therapeutic effect of SCS and the influence of epileptic seizure. First, SCS in the cervical spine was performed. The rats were divided into four groups: control group and treatment groups with SCS conducted at 2, 50, and 300 Hz frequency. Two days later, convulsions were induced by the intraperitoneal administration of kainic acid, followed by video monitoring to assess seizures. We also evaluated glial cells in the hippocampus by fluorescent immunostaining, electroencephalogram measurements, and inflammatory cytokines such as C-C motif chemokine ligand 2 (CCL2) by quantitative real-time polymerase chain reaction. Seizure frequency and the number of glial cells were significantly lower in the 300 Hz group than in the control group. SCS at 300 Hz decreased gene expression level of CCL2, which induces monocyte migration. SCS has anti-seizure effects by inhibiting CCL2-mediated cascades. The suppression of CCL2 and glial cells may be associated with the suppression of epileptic seizure.
Participants will receive rosuvastatin for 12 weeks followed by a 2 week washout period prior to the final follow-up visit. All patients will receive the study drug, and will serve as their own control. No participants will receive placebo. Rosuvastatin is FDA approved for treatment of high cholesterol, but its use in this trial is off label.
Intranasal oxytocin. 16 IU intranasal oxytocin x 5 days. One month interval between arms of treatment.
PURPOSE: A rapidly effective solid dispersing body of Scutellaria baicalensis Georgi extract and an oral formulation containing the same are provided to improve bioavailability and solubility. CONSTITUTION: A rapidly effective solid dispersing body contains Scutellaria baicalensis Georgi extact and water soluble polymer. The Scutellaria baicalensis Georgi extract contains Baicalein, Wogonin, or Oroxylin. The water soluble polymer polyvinylpyrolidone(PVP), poloxamer, methacrylic acid copolymer, or cellulose derivative. A method for manufacturing solid dispersing body comprises: a first step of adding water soluble polymer to Scutellaria baicalensis Georgi extract; and a second step of drying a dissolved product. The rapidly release oral formulation contains Scutellaria baicalensis Georgi extract, solid dispersing agent containing water soluble polymer, and pharmaceutically acceptable oral carrier or excipient.
PURPOSE: A cosmetic composition containing a microspicule for skin peeling is provided to ensure convenient use, to effectively remove skin dead cells without irritation, to normalize trouble skin, and to improve anti-wrinkling and elasticity by increasing collagen and elastin. CONSTITUTION: A cosmetic composition for low irritation skin peeling contains 1-10 wt% of a coated microspicule. The length and width of the microspicule are 100-300 micrometer and 10-20 micrometer, respectively. The coated microspicule is prepared by coating with sodium hyaluronic acid, PEG-60 hydrogenated castor oil, and disodium EDTA. The viscosity of the composition is 2800-3000 cps. The composition additionally contains one or more among a skin conditioning agent, a moisturizer, a pH adjusting agent, a biocide, a preservative, a solvent, and a chelating agent. The microspicule is derived from Spongilla. [Reference numerals] (a) Non-refined spicule; (b) Expanded image of the (a); (c) Refined pure spicule